The Article related to triazolopyrimidine preparation sar lsd1 kdm1a inhibitor anticancer activity, antiproliferative activity, lsd1 inhibitors, migration inhibition, [1,2,4]triazolo[1,5-a]pyrimidines and other aspects.Recommanded Product: 10472-24-9
On April 1, 2019, Wang, Shuai; Li, Zhong-Rui; Suo, Feng-Zhi; Yuan, Xiao-Han; Yu, Bin; Liu, Hong-Min published an article.Recommanded Product: 10472-24-9 The title of the article was Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1/KDM1A inhibitors. And the article contained the following:
The design, synthesis and biochem. characterization of [1,2,4]triazolo[1,5-a]pyrimidine derivatives I [R1 = H, [(2-bromophenyl)methyl]sulfanyl, prop-2-en-1-ylsulfanyl, [(1H-1,3-benzodiazol-2-ylmethyl)sulfanyl], etc.; R2 = H, Me, (CH2)4CH3; R3 = Me, Et, C6H5; R2, R3 = -(CH2)3-; R4 = H, C6H5, [4-(4-methylpiperazin-1-yl)phenyl], etc.] as new LSD1 inhibitors have been reported. Of these compounds, compound I [R1 = (1H-1,3-benzodiazol-2-ylsulfanyl)methyl; R2 = H; R3 = Me; R4 = [4-(4-methylpiperazin-1-yl)phenyl]] (II) inhibited LSD1 in a reversible manner (IC50 = 1.72 μM) and showed selectivity to LSD1 over MAO-A/B. Besides, compound II displayed FAD-competitive binding to LSD1. Interestingly, compound II did not inhibit horseradish peroxidase (HRP) and quench H2O2, thus excluding the possibility that LSD1 inhibition by compound II was due to the HRP inhibition and consumption of H2O2. In LSD1 overexpressed A549 cells, compound II concentration-dependently induced accumulation of H3K4me1/me2 and H3K9me2 and showed cellular target engagement to LSD1. Addnl., compound II significantly inhibited migration of A549 cells in a concentration-dependent manner, further western blot anal. showed that compound II increased expression levels of epithelial cell markers E-Cadherin and Claudin-1, down-regulated mesenchymal cell marker N-Cadherin and the upstream transcription factors Snail and Slug. Docking studies were also performed to rationalize the potency of compound II toward LSD1. To conclude, the [1,2,4]triazolo[1,5-a]pyrimidine I could serve as a promising scaffold for the development of new LSD1 inhibitors. The experimental process involved the reaction of Methyl 2-cyclopentanonecarboxylate(cas: 10472-24-9).Recommanded Product: 10472-24-9
The Article related to triazolopyrimidine preparation sar lsd1 kdm1a inhibitor anticancer activity, antiproliferative activity, lsd1 inhibitors, migration inhibition, [1,2,4]triazolo[1,5-a]pyrimidines and other aspects.Recommanded Product: 10472-24-9
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics